SMMT241115P10000
- 0.05
- 0.000.00%
Summit Therapeutics Newsroom
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
Merck to Buy Rights to Chinese Cancer Drug for up to $3.3B
PRIVACY ALERT: Summit Pathology Under Investigation for Data Breach of Over 1.8 Million Patient Records
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
AppLovin's Stock Easily Seals Its Best Week Ever. It's Now up 600% This Year.
For the 4th Time, Summit Medical Staffing Makes the Inc. 5000, at No. 126 in 2024
Why Summit Therapeutics Stock Was a Winner Today
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
This Tencent Music Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
JMP Securities Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $32
Express News | JMP Securities Initiates Coverage On Summit Therapeutics With Market Outperform Rating, Announces Price Target of $32
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $44
Express News | Summit Therapeutics PLC : H.c. Wainwright Cuts Target Price to $44 From $45
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight
Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript Summary
Summit Therapeutics | 10-Q: Q3 2024 Earnings Report
Summit Therapeutics Q3 Adj $(0.05) Beats $(0.07) Estimate